<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123873</url>
  </required_header>
  <id_info>
    <org_study_id>SM1-JOAST-2019</org_study_id>
    <nct_id>NCT04123873</nct_id>
  </id_info>
  <brief_title>Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty</brief_title>
  <acronym>RECIPE</acronym>
  <official_title>Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty. The RECIPE Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multimodal pain management is essential for recovery after surgery, aiming to target
      different pain mechanisms to minimize opioid usage and opioid-related adverse effects.
      Evidence for benefits and harms of various non-opioid analgesic combinations is, however,
      nearly non-existing, and large-scale trials are urgently needed.

      Recently, the investigators have demonstrated that combining paracetamol and ibuprofen is
      superior to each single drug when assessing pain after hip replacement. Further improvement
      is needed, investigating additional non-opioid analgesics to this combination.
      Glucocorticoids have anti-emetic and analgesic properties, but evidence for analgesic
      efficacy in combination with paracetamol and ibuprofen is lacking.

      The RECIPE trial is an investigator-initiated randomized, placebo-controlled, parallel,
      4-group, blinded multicentre trial with 90-day follow-up investigating benefits and harms of
      different combinations of paracetamol, ibuprofen, and dexamethasone for patients undergoing
      total hip arthroplasty.

      The primary outcome is total use of IV morphine 0-24 hours postoperatively. Secondary
      outcomes are pain (upon mobilisation, at rest, and during 5 m walk), and adverse events.
      Exploratory outcomes include quality of sleep, opioid-related adverse effects, serious
      adverse events (&lt; 90 days), and patient reported disability score and quality of life (at 90
      days).

      Based on sample-size calculations, 1060 patients are needed to detect a minimal clinically
      important difference in 24-hour morphine consumption of 8 mg, using a familywise type 1 error
      rate of 0.05 and a type 2 error rate of 0.2. The primary analyses will be based on the
      intention to treat population. More than six Danish university- and regional hospitals will
      participate in the trial.

      With this trial the investigators expect to lay the foundation for the best postoperative
      multimodal analgesic regimen for both total hip arthroplasty and possibly other surgeries,
      thereby facilitating recovery for millions of future surgical patients worldwide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study medication will be masked by the pharmacy. The experimental medicine will be packed and labelled by Skanderborg Pharmacy in accordance with the Good Manufacturing Practice regulations. The sponsor has a set of sealed, opaque envelopes with the participants' allocation, and these will only be revealed for the investigators when the data has been analysed and abstracts and conclusions covering the different possibilities for interpreting the trial results, have been agreed upon by the steering committee</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative morphine-consumption during the first 24 hours after end of surgery</measure>
    <time_frame>0-24 hours after end of surgery</time_frame>
    <description>Total need for IV-morphine mg (eqv) for the first 24 hours postoperatively, administered as patient-controlled analgesia (PCA)-morphine (0-24 hours), and supplemental opioid administered at the post-anaesthesia care unit the first hour postoperatively after end of surgery (general anaesthesia) or end of spinal anaesthesia, or any supplemental opioid given at the ward</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores during mobilisation 24h</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) with active 30 degrees flexion of the hip No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest 24h</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Pain scores at rest (VAS) No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum level of pain</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Maximum level of pain (VAS) during walk of 5 meters No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Number of patients with one or more AEs in the intervention period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Within 90 days</time_frame>
    <description>SAEs, including death, within 90 days after surgery defined as SAE (according to ICH-GCP-guidelines) except 'prolongation of hospitalisation'</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain scores during mobilisation 6h</measure>
    <time_frame>6 hours after end of surgery</time_frame>
    <description>Pain scores (VAS) with active 30 degrees flexion of the hip No pain = 0; worst imaginable pain = 100</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain scores at rest 6h</measure>
    <time_frame>6 hours after end of surgery</time_frame>
    <description>Pain scores (VAS) at rest No pain = 0; worst imaginable pain = 100</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of nausea</measure>
    <time_frame>6 and 24 hours after end of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of vomiting episodes</measure>
    <time_frame>0-24 after end of surgery. Reported by interview 24 hours after end of surgery</time_frame>
    <description>The number of productive vomiting events (volume estimated over 10 ml) is recorded corresponding to the period 0-24 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumption of ondansetron and DHBP</measure>
    <time_frame>0-24 hours after end of surgery</time_frame>
    <description>Consumption fon ondansetron and DHBP in mg</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of dizziness during mobilization</measure>
    <time_frame>24 hours after end of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood loss</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Blood loss during the surgical procedure in ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of sleep (VAS)</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Quality of sleep (VAS) Worst possible sleep = 0; best possible sleep = 100</description>
  </other_outcome>
  <other_outcome>
    <measure>Days alive and outside hospital within 90 days after surgery</measure>
    <time_frame>Within 90 days after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hip disability and Osteoarthritis Outcome Score</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>5 point Lipert-scale 0 to 4 (no, mild, moderate, severe and extreme)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>EuroQol five dimensions 5 point Lipert scale (EQ-5D-5L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid use</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>Patient consumption of opioids within 90 days after surgery</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>Pain, Acute</condition>
  <condition>Hip Arthropathy</condition>
  <condition>Analgesia</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
Plus placebo (matching DXM) IV administered after induction of anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
Plus DXM 24 mg IV after induction of anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
Plus DXM 24 mg IV after induction of anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
Plus DXM 24 mg IV after induction of anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>1g x 4 p.o.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen (400 mg x 4)</intervention_name>
    <description>400mg x 4 p.o.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>24mg IV x 1 after induction om anaesthesia</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet (x 4)</intervention_name>
    <description>p.o. x 4</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV (x 1)</intervention_name>
    <description>IV x 1</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for elective, unilateral, primary THA

          -  Age ≥ 18

          -  ASA 1-3

          -  BMI &gt; 18 and &lt; 40

          -  Negative urine HCG pregnancy test and use of anti-conception for women in the fertile
             age

          -  Give written informed consent to participate in the trial after having fully
             understood the contents of the protocol and restrictions

        Exclusion Criteria:

          -  Patients who cannot cooperate with the trial

          -  Concomitant participation in another trial involving medication

          -  Patients who cannot understand or speak Danish

          -  Patients with allergy to medication used in the trial

          -  Patients with daily use of high dose opioid (&gt; oral morphine 30 mg/day or oxycodone 30
             mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and
             transdermal opioids.

          -  Patients with daily use of systemic glucocorticoids (within 3 months before the trial)

          -  Contraindications against ibuprofen or paracetamol, for example previous ulcer, known
             heart failure, known liver failure, or known renal failure (eGRF &lt; 60 ml/kg/1,73m2),
             known thrombocytopenia (&lt; 100 x 109/l); or against treatment with glucocorticoids

          -  Dysregulated diabetes (investigator's judgement)

          -  Patients suffering from alcohol and/or drug abuse - based on the investigator's
             judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Hägi-Pedersen, MD, PhD</last_name>
    <phone>0045 21517167</phone>
    <email>dhag@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joakim Steiness, MD</last_name>
    <email>joast@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gildhøj Privathospital</name>
      <address>
        <city>København</city>
        <state>Brøndby</state>
        <zip>2605</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Anker Pedersen, MD</last_name>
      <email>nap@gildhoj.dk</email>
    </contact>
    <investigator>
      <last_name>Niels Anker Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Næstved-Slagelse-Ringsted Hospitals</name>
      <address>
        <city>Næstved</city>
        <state>Danmark</state>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Hägi-Pedersen, Ph.D.</last_name>
      <phone>+45 56514792</phone>
      <email>dhag@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Joakim Steiness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kjeld Søballe</last_name>
      <email>kjeld@soballe.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels H Lunn, DMSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Grevstad, MD, PhD</last_name>
      <email>ulrik.grevstad@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Køge Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole Matiesen, MD, PhD</last_name>
      <email>omat@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Ole Matiesen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (OUH)</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Overgaard, MD, DMsc</last_name>
      <phone>+45 59484105</phone>
      <email>soeren.overgaard@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RECIPE</keyword>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Multimodal analgesia</keyword>
  <keyword>Non-opioid analgesia</keyword>
  <keyword>Acute pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

